Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

ABBV - Abbvie Inc

Close
196.31
1.130   0.576%

Share volume: 3,819,287
Last Updated: Fri 30 Aug 2024 10:00:03 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%
$195.18
1.13
0.58%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
54%
Profitability 50%
Dept financing 50%
Liquidity 12%
Performance 71%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-0.63%
1 Month
5.10%
3 Months
26.74%
6 Months
12.34%
1 Year
37.47%
2 Year
56.52%
Key data
Stock price
$196.31
P/E Ratio 
65.45
DAY RANGE
$194.17 - $196.50
EPS 
$2.99
52 WEEK RANGE
$132.11 - $198.30
52 WEEK CHANGE
$0.38
MARKET CAP 
346.751 B
YIELD 
3.08%
SHARES OUTSTANDING 
1.766 B
DIVIDEND
$1.55
EX-DIVIDEND DATE
07/15/2024
NEXT EARNINGS DATE
10/25/2024
BETA 
0.29
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$3,907,627
AVERAGE 30 VOLUME 
$4,415,161
Company detail
CEO: Richard Gonzalez
Region: US
Website: https://www.abbvie.com/
Employees: 50,000
IPO year: -
Issue type: Common Stock
Market: NYSE
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

AbbVie Inc. is a pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. Their primary product is Humira (adalimumab) ($21 billion in 2022 revenues, 37% of total), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohns disease, plaque psoriasis, and ulcerative colitis.

Recent news